| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.05. | Spyre Therapeutics Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
| 09.05. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.05. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | 61 | PR Newswire | SPY001, an anti-a4ß7 antibody engineered for infrequent, subcutaneous dosing successfully completed a 28-day GLP toxicity study and remains on track to begin first-in-human studies in the second quarter... ► Artikel lesen | |
| 03.05. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 114 | PR Newswire | WALTHAM, Mass., May 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering... ► Artikel lesen | |
| 25.04. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.03. | Spyre Therapeutics, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 04.03. | Spyre Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 01.03. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 320 | PR Newswire | WALTHAM, Mass., March 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering... ► Artikel lesen | |
| 01.03. | Spyre Therapeutics, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 01.03. | Spyre Therapeutics, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 29.02. | Spyre Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 29.02. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.02. | Spyre Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 29.02. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | 191 | PR Newswire | Announced corporate name change to Spyre Therapeutics; appointment of Cameron Turtle, DPhil, as Chief Executive Officer; and began trading on Nasdaq under the symbol "SYRE"
SPY001, an anti-a4ß7 antibody... ► Artikel lesen | |
| 05.02. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Spyre Therapeutics, Inc.: Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors | 163 | PR Newswire | WALTHAM, Mass., Feb. 5, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering... ► Artikel lesen | |
| 03.02. | Spyre Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 18.01. | Spyre Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 22.12.23 | Spyre Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NEL | 3.276 |
| GAMESTOP | 3.085 |
| NVIDIA | 2.806 |
| EVOTEC | 2.536 |
| TUI | 1.623 |
| BAYER | 1.394 |
| BIONTECH | 1.067 |
| PLUG POWER | 950 |
| RHEINMETALL | 854 |
| VOLKSWAGEN | 739 |
| DEUTSCHE LUFTHANSA | 732 |
| BYD | 691 |
| SUPER MICRO COMPUTER | 689 |
| SIEMENS ENERGY | 682 |
| MERCEDES-BENZ | 616 |
| COMMERZBANK | 586 |
| TESLA | 567 |
| AIXTRON SE | 539 |
| HEIDELBERGER DRUCK | 529 |
| RWE | 519 |
| DEUTSCHE BANK | 516 |
| RENK GROUP | 489 |
| AMC ENTERTAINMENT | 479 |
| BASF | 475 |
| ADLER GROUP | 444 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
